🇺🇸 FDA
Pipeline program

OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

10353

Phase 2 small_molecule active

Quick answer

OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89 for Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy. is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials